Drug Type TCR therapy |
Synonyms |
Target |
Mechanism NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
LAGE-1a Positive Solid Tumors | Phase 1 | SE | 21 Dec 2020 | |
LAGE-1a Positive Solid Tumors | Phase 1 | AU | 21 Dec 2020 | |
LAGE-1a Positive Solid Tumors | Phase 1 | US | 21 Dec 2020 | |
LAGE-1a Positive Solid Tumors | Phase 1 | NL | 21 Dec 2020 | |
LAGE-1a Positive Solid Tumors | Phase 1 | CA | 21 Dec 2020 | |
LAGE-1a Positive Solid Tumors | Phase 1 | DE | 21 Dec 2020 | |
Synovial Sarcoma | Phase 1 | US | 21 Dec 2020 | |
Synovial Sarcoma | Phase 1 | NL | 21 Dec 2020 | |
Synovial Sarcoma | Phase 1 | DE | 21 Dec 2020 | |
Synovial Sarcoma | Phase 1 | SE | 21 Dec 2020 |